- Home
- CNOBP vs IMNM Comparison
CNOBP vs IMNM Comparison
Compare CNOBP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOBP
- IMNM
- Stock Information
- Founded
- CNOBP N/A
- IMNM 2006
- Country
- CNOBP United States
- IMNM United States
- Employees
- CNOBP 493
- IMNM N/A
- Industry
- CNOBP Major Banks
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- CNOBP Finance
- IMNM Health Care
- Exchange
- CNOBP Nasdaq
- IMNM Nasdaq
- Market Cap
- CNOBP N/A
- IMNM 748.3M
- IPO Year
- CNOBP N/A
- IMNM 2020
- Fundamental
- Price
- CNOBP $23.09
- IMNM $8.77
- Analyst Decision
- CNOBP
- IMNM Strong Buy
- Analyst Count
- CNOBP 0
- IMNM 5
- Target Price
- CNOBP N/A
- IMNM $26.40
- AVG Volume (30 Days)
- CNOBP N/A
- IMNM 1.1M
- Earning Date
- CNOBP N/A
- IMNM 08-11-2025
- Dividend Yield
- CNOBP N/A
- IMNM N/A
- EPS Growth
- CNOBP N/A
- IMNM N/A
- EPS
- CNOBP N/A
- IMNM N/A
- Revenue
- CNOBP N/A
- IMNM $10,938,000.00
- Revenue This Year
- CNOBP N/A
- IMNM N/A
- Revenue Next Year
- CNOBP N/A
- IMNM $310.65
- P/E Ratio
- CNOBP N/A
- IMNM N/A
- Revenue Growth
- CNOBP N/A
- IMNM N/A
- 52 Week Low
- CNOBP N/A
- IMNM $5.15
- 52 Week High
- CNOBP N/A
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- CNOBP 57.87
- IMNM 49.38
- Support Level
- CNOBP $22.86
- IMNM $8.60
- Resistance Level
- CNOBP $23.08
- IMNM $9.27
- Average True Range (ATR)
- CNOBP 0.12
- IMNM 0.46
- MACD
- CNOBP 0.00
- IMNM -0.03
- Stochastic Oscillator
- CNOBP 87.76
- IMNM 44.57
About CNOBP ConnectOne Bancorp Inc. Depositary Shares each representing a 1/40th interest in a share of 5.25% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series A
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.